Nohla Therapeutics Inc. — Form D/A
Nohla Therapeutics Inc. of SEATTLE, WA, a company, filed a Form D amendment with the SEC on 2017-11-16. The offering totals $41.5M, of which $32.4M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2017-11-16
- Form: D/A
- Accession: 0001662002-17-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $41.5M
- Amount sold: $32.4M
- Remaining: $9.2M
- Investors: 13
- Date of first sale: 2016-11-18
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-275626
Issuer
- Name: Nohla Therapeutics Inc.
- CIK: 0001662002
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 1600 Fairview Ave E., SEATTLE, WA, 98102
- Phone: 206-519-5300
Officers, directors & promoters (17)
| Name | Role | Location |
|---|
| Steven Gillis | Director | South San Francisco, CA |
| Darren Scotti | Executive Officer | Fort Collins, CO |
| Lawrence Gozlan | Director | Fort Collins, CO |
| Michael Sistenich | Director | Fort Collins, CO |
| Michael Sistenich | Executive Officer | Fort Collins, CO |
| Colleen Delaney | Executive Officer | Wexford, PA |
| Kathleen Fanning | Director | CAMBRIDGE, MA |
| Kathleen Fanning | Executive Officer | CAMBRIDGE, MA |
| Jim Johnson | Executive Officer | AUSTIN, TX |
| Brian Daniels | Director | Villanova, PA |
| Gary Christianson | Executive Officer | Seattle, WA |
| Lawrence David Gozlan | Director | Seattle, WA |
| Ian David Brown | Director | Seattle, WA |
| Darren David Scotti | Executive Officer | Seattle, WA |
| Benjamin Scot Bergo | Director | Seattle, WA |
| Benjamin Scot Bergo | Executive Officer | Seattle, WA |
| Benjamin Scot Bergo | Promoter | Seattle, WA |
Other filings by this issuer (3)
More